Secondary organising pneumonia caused by denosumab
  • Djalaleddine Ouakidi
    Department of Pulmonology, Faculty of Medicine, University of Oran 1, Algeria
  • Bouchra Nesrine Bourouis
    Department of Pulmonology, Faculty of Medicine, University of Oran 1, Algeria
  • Mohammed Amine Banat
    Department of Pulmonology, Faculty of Medicine, University of Oran 1, Algeria
  • Nesrine Azzi
    Department of Pulmonology, Faculty of Medicine, University of Oran 1, Algeria
  • Siham Benzait
    Department of Pulmonology, Faculty of Medicine, University of Oran 1, Algeria
  • Abdelmadjid Snouber
    Department of Pulmonology, Faculty of Medicine, University of Oran 1, Algeria

Keywords

Denosumab, secondary organising pneumonia, interstitial lung disease, osteoporosis

Abstract

Introduction: Organising pneumonia belongs to diffuse interstitial lung diseases; we distinguish the cryptogenic organising pneumonia, which is idiopathic, from the secondary organising pneumonia caused by drugs or a defined cause. Denosumab is a human monoclonal antibody, rarely inducing adverse pulmonary effects.
Case description: A 57-year-old female patient was admitted to our chest clinic for acute respiratory distress. She was treated with denosumab for severe osteoporosis. The patient described a dry cough and dyspnoea over the previous four months, increased after the last injection of denosumab. A high-resolution computed tomography scan showed bilateral basal parenchymal condensations. The aetiological investigation did not reveal any infectious or immunological origin. The favourable computed tomography imaging and clinical evolution after corticosteroid therapy led to the diagnosis of drug-induced organising pneumonia.
Conclusion: Denosumab could induce organising pneumonia. Therefore, clinicians should be aware of this pulmonary toxicity.

VIEW THE ENTIRE ARTICLE

References

  • Kasemchaiyanun A, Boonsarngsuk V, Liamsombut S, Incharoen P, Sukkasem W. Myeloperoxidase-antineutrophil cytoplasmic antibody-associated diffuse alveolar hemorrhage caused by denosumab. Respir Med Case Rep 2022;38:101690.
  • Liu W, Zhang X. Receptor activator of nuclear factor-KB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues. Mol Med Rep 2015;11:3212–3218.
  • Boorsma C, Draijer C, Cool R, Brandsma C-A, Nossent G, Heukels P, et al. The RANKL-OPG balance in pulmonary fibrosis. Eur Respir J 2015;46:PA3809.
  • Lamy O, Gonzalez-Rodriguez E, Stoll D, Aubry-Rozier B. Denosumab in clinical practice: beware before, during and after. Rev Med Suisse 2017;13:863–866.
  • Lewiecki EM. New and emerging concepts in the use of denosumab for the treatment of osteoporosis. Ther Adv Musculoskel Dis 2018;10 209–223.
  • Amgen Inc. Proliaprescribing.information. https://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/prolia/proliapi.ahsx [2018, accessed 16 July 2018].
  • Ruiz AC, Carrascosa MF, Concha ST, Gil AH, Rivero JG. Interstitial lung disease in a patient treated with denosumab. Eur J Case Rep Intern Med 2019;6:001131.
  • Mori Y, Izumiyama T, Mori N, Aizawa T. Interstitial lung disease in a woman with rheumatoid arthritis treated with denosumab: a case report. Mod Rheumatol Case Rep 2021;6:155–159.
  • Sanchez A, Lozier M, Adkinson BC, Ilaiwy A. c-ANCA vasculitis after initiation of denosumab. BMJ Case Rep 2019;12:e228336.
  • Komada F, Nakayama Y, Takara K. Analysis of time-to-onset and onset-pattern of interstitial lung disease after the administration of monoclonal antibody agents. Yakugaku Zasshi 2018;138:1587–1594.
  • Li Y, Han F, Yu H, Yang T, Li H, Guan W, et al. Case report cryptogenic organising pneumonia: clinical, pathological, and prognostic analysis of 27 cases. Int J Clin Exp Med 2016;9:6911–6919.
  • Pneumotox. Organizing pneumonia pattern (an area or areas of consolidation on imaging). https://www.pneumotox.com/pattern/view/5/I.d/organizing-pneumonia-pattern-an-area-or-areas-of-consolidation-on-imaging [Accessed 26 Mar 2023].
  • Nakashima K, Naito T, Omori S, Yoshikawa S, Endo M, Kiyohara Y, et al. Organizing pneumonia induced by nivolumab in a patient with metastatic melanoma. J Thorac Oncol 2015;11:432–433.
  • Ikegawa K, Hanaoka M, Ushiki A, Yamamoto H, Kubo KA. A case of organizing pneumonia induced by tocilizumab. Intern Med 2011;50:2191–2193.
  • Ergin AB, Fong N, Daw HA. Rituximab-induced bronchiolitis obliterans organizing pneumonia. Case Rep Med 2012;680431.
  • Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.
  • Cottin V, Cordier JF. Cryptogenic organizing pneumonia. Semin Respir Crit Care Med 2012;33:462–475.

    • Views: 374
    HTML downloads: 62
    PDF downloads: 352

    Published: 2023-09-15
    Issue: 2023: Vol 10 No 10 (view)

    How to cite:
    1.
    Ouakidi D, Bourouis BN, Banat MA, Azzi N, Benzait S, Snouber A. Secondary organising pneumonia caused by denosumab. EJCRIM 2023;10 doi:10.12890/2023_004043.